Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

189.97 -0.23 (-0.12%)
Streaming Delayed Price Updated: 2:57 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
News headline image
3 Healthcare Stocks That Fall Short
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
News headline image
AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Trump Administration Review Targets Medical Supply Chain Vulnerabilities ↗
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign... 
Via Benzinga
Topics Economy Government Supply Chain
News headline image
What Does the Market Think About Illumina? ↗
 
Via Benzinga
News headline image
The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
News headline image
Why Illumina (ILMN) Stock Is Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.2% in the afternoon session after reports emerged of increased competition from a Chinese rival and news of a significant legal settlement. 
Via StockStory
Topics Economy Lawsuit Whistleblower
News headline image
Astrana Health, Privia Health, Illumina, Waters Corporation, and LeMaitre Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
News headline image
Illumina (ILMN): Buy, Sell, or Hold Post Q2 Earnings?
Illumina has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.6% to $98.50 per share while the index has gained 15.5%. 
Via StockStory
Topics Government Stocks
News headline image
ILLUMINA INC (NASDAQ:ILMN) Screens as a Decent Value Stock for Investors ↗
Discover Illumina Inc (ILMN), a potential value investing opportunity with strong valuation, profitability, and solid growth forecasts. 
Via Chartmill
News headline image
Life Sciences Tools & Services Stocks Q2 Results: Benchmarking Illumina (NASDAQ:ILMN)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life sciences tools & services industry, including Illumina (NASDAQ:ILMN) and its... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
AdaptHealth, Illumina, Globalstar, Iridium, and Alight Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics ETFs Economy
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited ↗
Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF. 
Via Benzinga
News headline image
NICE Stock Stops Being Nice, Has A Bearish Breakdown ↗
NICE Ltd. has ended a 15-year trend with a bearish breakdown, signaling extended downside risk. Here's what the Adhishthana Principles reveal... 
Via Benzinga
News headline image
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
News headline image
Illumina’s Q2 Earnings Call: Our Top 5 Analyst Questions
Illumina’s second quarter performance in 2025 was met with a significant negative market reaction, as shares declined in response to ongoing revenue contraction and sharply lower operating margins.... 
Via StockStory
Topics Earnings World Trade
News headline image
ILMN Q2 Deep Dive: Clinical Demand Cushions Revenue Decline Amid Research Weakness and Margin Pressures
Genomics company Illumina (NASDAQ:ILMN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $1.19 per share... 
Via StockStory
News headline image
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. 
Via StockStory
Topics Bonds Economy Stocks
News headline image
Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit ↗
Illumina will pay $9.8 million to settle allegations it sold genomic systems with cybersecurity flaws to U.S. agencies. A whistleblower will receive $1.9 million. 
Via Benzinga
Topics Whistleblower
News headline image
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
Illumina (ILMN) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Cathie Wood's Ark Invest Loads Up On Coinbase, Roku, Illumina, And Bitmine Immersion ↗
Cathie Wood-led Ark Invest made significant trades in COIN, ROKU, ILMN, and BMNR. They also bought PD and SOFI, sold KTOS and RBLX. 
Via Benzinga
News headline image
Illumina (ILMN) Q2 EPS Jumps 9% ↗
Via The Motley Fool
News headline image
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.1% in the afternoon session as investors reacted to its second-quarter earnings report, where a year-over-year revenue decline overshadowed... 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results ↗
 
Via Benzinga
News headline image
Illumina: A 5.2 Rating Amid Challenges and Opportunities ↗
Via The Motley Fool
News headline image
Illumina Inc (NASDAQ:ILMN) Q2 2025 Earnings: Mixed Results with Revenue Miss and EPS Beat ↗
Illumina's Q2 2025 earnings show mixed results: revenue missed estimates at $1.059B (-3% YoY), but EPS beat at $1.19. Shares dipped 1.18% post-report. 
Via Chartmill
News headline image
Illumina (NASDAQ:ILMN) Surprises With Q2 Sales
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $0.36 per share was 64.4% below... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.